Chief executive of Array BioPharma resigns

Chairman Kyle Lefkoff will lead effort to replace Robert Conway

Robert Conway has resigned as chief executive of Array BioPharma, a US biotechnology company, for personal reasons. The board has appointed chairman Kyle Lefkoff to serve as executive chairman to oversee the company in the interim and lead the effort to identify a new chief executive.

Lefkoff said he will work with the Array management team to ensure a smooth transition and continued advancement of the company’s multiple clinical programmes in cancer and inflammation and supporting our many partnered programmes.

You may also like

Research & Development

Array Biopharma and Genentech to progress ChK-1 programme

Genentech will pay US$28m upfront payment to Array
Finance

Array BioPharma to cut jobs in restructure

Will focus on development of key clinical programmes
Research & Development

Array BioPharma signs strategic oncology collaboration

Agreement with Novartis will advance aim to become integrated, commercial-stage biopharma company
Pharmaceutical

Enanta Pharma files patent infringement suit against Pfizer in the Unified Patent Court of the EU

The company is seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the 265 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets)
Pharmaceutical

Driving excellence in aseptic fill-finish

Driving excellence in aseptic fill-finish | 3P innovation's strategic partnership with Stäubli Robotics
Manufacturing

Alex Jezequel talks about designing roboFIL

Interview with Alex Jezequel, Projects Director at 3P innovation: roboFIL: revolutionising pharmaceutical fill-finish operations
Regulatory

The foundations of pharmaceutical compliance for beginners

Whether you’re stepping into the pharmaceutical industry for the first time or pivoting into a compliance or quality assurance role after years of experience, mastering the fundamentals of quality and regulatory compliance is vital to your success—and to the success of your organisation
Subscribe now